Skip to main content
Caplight Logo









Entegrion

Entegrion

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://entegrion.com/

Last Round

Series D

Jul 5, 2022

Total Funding Raised

$89.34M

Company Overview

Entegrion is a life sciences company that develops and manufactures diagnostic tools designed for the clinical diagnosis and management of hemostasis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Defense Tech, Biotech Equipment

Business Model

B2G

Customer Profile

Government Contracts, Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

hemostasis managementcoagulation monitoringViscoelastic Coagulation MonitorVCMviscoelastic testingpoint-of-care testingPOC testingmilitary medicinemedical device manufacturertrauma diagnosticscombat casualty carecritical care diagnosticscoagulation analyzerdefense contractorveterinary diagnosticsgovernment contractsB2G

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Entegrion Comparables

Compare Entegrion with similar companies based on industry and business-model similarity.

Entegrion comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perosphere Technologies Inc.
82%
Sienco, Inc.
81%
FloBio
79%

Entegrion Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJul 5, 2022
GrantJul 31, 2012
GrantOct 4, 2011
GrantAug 25, 2011
Early FundingMar 31, 2011
Grant
Aug 6, 2009

Key People

Founding team and executive leadership

John Mowell

CEO - Chairman

Executive Team

Entegrion Investors

Notable investors and investment history

Entegrion investors
InvestorRounds
United States Department of DefenseGrant
Office of Naval ResearchGrant
U.S. NavyGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 108% MoM.

  • Jan 7, 2026

    Monthly visitors increased 155% MoM.

Entegrion Filings

Explore SEC and related filing metadata, where available.

Entegrion filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Entegrion's valuation, stock price, and market status.

Is Entegrion a public or private company?

Entegrion is a private company.

What is the current stock price of Entegrion?

Entegrion is a private company with no public stock price. No recent secondary market data is available.

How much is Entegrion worth (valuation)?

Valuation information for Entegrion is not publicly available.

Can I buy Entegrion stock?

Entegrion shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Entegrion's last funding round?

Entegrion's most recent funding round was Series D on July 5, 2022.

Who are the main investors in Entegrion?

Key investors in Entegrion include United States Department of Defense, Office of Naval Research, U.S. Navy.

Will Entegrion IPO soon?

No public IPO plans have been announced for Entegrion.

How can I track Entegrion secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Entegrion's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range7
Year Founded2002
Last FundingJul 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?